Drug Profile
Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group
Alternative Names: AK 105 - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group; AnnikoLatest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Developer Akeso Biopharma; Beijing Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group; Fudan University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer
- Phase III Liver cancer
- Phase II Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
- Phase I/II Mesothelioma; Oesophageal cancer; Thymoma; Uterine cancer
Most Recent Events
- 23 Jan 2024 Phase-I/II clinical trials in Cholangiocarcinoma (Combination therapy) (IV) before January 2024 (Akeso Biopharma pipeline, January 2024)
- 23 Jan 2024 Phase-I/II clinical trials in Gastric cancer (Combination therapy) (IV) before January 2024 (Akeso Biopharma pipeline, January 2024)
- 23 Jan 2024 Phase-I/II clinical trials in Head and neck cancer (Combination therapy) (IV) before January 2024 (Akeso Biopharma pipeline, January 2024)